KHTRF News and Press, Knight Therapeutics Inc From 08/25/20

Health Canada approves TherapeuticsMD (NASDAQ: TXMD ) and Knight Therapeutics' ( OTC:KHTRF )  Imvexxy for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). More news on: TherapeuticsMD, Inc., Knight Therapeutics In...

Knight Therapeutics Inc. (KHTRF) Q2 2020 Earnings Conference Call August 13, 2020 8:30 AM ET Company Participants Jonathan Ross Goodman - Chief Executive Officer Samira Sakhia - President and Chief Operating Officer Amal Khouri - Vice President, Business Development Arvind Utch...

Knight Therapeutics ( OTC:KHTRF ) and its subsidiary 1178991 Canada Inc. announce the launch of tender offer and notification for the offer process for the acquisition and delisting of all outstanding Brazilian Depositary Receipts of Biotoscana Investments S.A. More news on: Knight The...

Knight Therapeutics Inc. (KHTRF) Q1 2020 Earnings Conference Call June 26, 2020 08:30 AM ET Company Participants Jonathan Ross Goodman - CEO Samira Sakhia - President and COO Amal Khouri - VP, Business Development Arvind Utchanah - CFO Conference Call Participants David N...

Knight Therapeutics Inc. (KHTRF) Q4 2019 Earnings Conference Call March 30, 2020 5:30 PM ET Company Participants Jonathan Ross Goodman – Chief Executive Officer Samira Sakhia – President Amal Khouri – Vice President-Business Development Arvind Utchanah ...

Knight Therapeutics ( OTC:KHTRF ): FY GAAP EPS of C$0.10. More news on: Knight Therapeutics Inc., Earnings news and commentary, Read more ...

MONTREAL and LAUSANNE, Switzerland , Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex- USA ) specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, today announced that they have entered into an ex...

Knight Therapeutics' ( OTC:KHTRF ) New Drug Submission (NDS) for BIJUVA has been accepted for review by Health Canada. More news on: Knight Therapeutics Inc., TherapeuticsMD, Inc., Healthcare stocks news, Read more ...

Knight Therapeutics Inc. (KHTRF) Q3 2019 Earnings Conference Call November 12, 2019 5:00 PM ET Company Participants Jonathan Ross Goodman - Chief Executive Officer Samira Sakhia - President & Chief Financial Officer Amal Khouri - Vice President of Business Development Arvin...

Knight Therapeutics ( OTC:KHTRF ): Q3 GAAP EPS of -C$0.021. More news on: Knight Therapeutics Inc., Earnings news and commentary, Read more ...